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Introduction
Methods and Materials

●

●

Surgical intervention is often used in the management of cancers.1
○ Discrimination between malignant and healthy tissue is a major
obstacle that can lead to insufficient tumor resection.1
Use of a dual-modality imaging agent with both magnetic
resonance imaging (MRI) and Optical Imaging properties could
potentially improve tumor visualization before and during surgery
(Figure 1).2,3
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Project Goal

Lanthanide ions such as Europium possess long-lived
luminescence lifetimes, making them ideal candidates for bimodal
imaging probes.
○ To obtain high-resolution images, however, high energy laser
excitation is required, which can be damaging to biological
tissue.
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The goal of this project is to synthesize a library of Europium (III)
complexes and determine which has optimal luminescence and
MRI properties.
Our hypothesis is that the variation among the quinoline antennas
will alter the optical imaging properties, which will be reflected in
the luminescence intensities of the complexes.
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Figure 1. View of localized cancerous region with the naked eye (left) and
with the aid of a tumor-targeted fluorescent dye (right).3
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To overcome this limitation, an organic chromophore can be used
as an “antenna” to sensitize the luminescence of the lanthanide ion
upon excitation from a lower energy light source.
The efficiency of this sensitization process is influenced by the
nature of, and the distance from the lanthanide ion.

Ligand Synthesis
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All reagents and solvents were purchased
from commercial vendors and used as
received.
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Figure 2. Visual diagram of the antenna effect.⁴
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Reagents and Materials
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Metal Complexation
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Ligands were synthesized according to
Scheme 1. Cyclen was monoalkylated with
the appropriate quinoline sidearm and
purified by pH extractions. The resulting
products
were
reacted
with
2bromoacetamide
and isolated from the
reaction mixture by filtration. All ligand
identities were verified by 1H and 13C NMR
spectroscopy.
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Scheme 1. Synthetic scheme for Eu³⁺ complex library

Results and Discussion

Europium complexes were prepared by
mixing equimolar amounts of EuCl3 and
ligand at pH 5.5-6. The absence of excess
metal in solution was confirmed with a
Xylenol Orange Test.

Conclusion
●
●

●

Amide substituent location affects optical imaging
properties.
Eu-30 has the highest emission intensity but is the
least stable compound while Eu-48 has the lowest
emission but is the most stable. Due to this, both
compounds are not ideal candidates for dual modality
imaging agents.
Compounds Eu-43, Eu-46, and Eu-47 possess the
highest level of stability and emission intensity. These
complexes show the most promise for further study.

Future Work
●

Figure 3. Emission spectra of 1E-4 M Eu3+ complexes in 0.1 M HEPES
buffer (pH 7.4). Emission spectra were acquired upon excitation at
wavelengths specific to each complex.

Evaluation of Spectroscopic Properties
●

●

●
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The emission spectra shown in Figure 3 demonstrates
luminescence sensitization via the quinoline antenna.
○ The differences in intensities can be attributed to the
differences in coordination sites and amide
substituent location.
The luminescence intensities are far greater when the
quinoline is excited in comparison to direct excitation of
the metal ion (Figure 4).
○ This indicates that the quinoline is effectively
sensitizing the luminescence of the lanthanide ions.
Eu-30 exhibits the highest emission intensity due to the
direct coordination (shorter distance) of the quinoline
antenna with the Eu3+ ion.
Eu-45 and Eu-48 exhibit the lowest emission
intensities.

Figure 4. Comparison of the area under the emission curve for
each complex upon antenna excitation (blue) and direct lanthanide
excitation (red).

Figure 6. Normalized emission intensities of Eu3+ complexes following
incubation in citrate buffer (10 mM, pH 3) over 48 hours at 310 K.
Dashed lines represent mono-exponential decay fits of the data.

Measurement of Stability
●

●
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Figure 5. From left to right, Eu-30, Eu-42, Eu-43, Eu-44, Eu45, Eu-46, Eu-47, and Eu-48 (1E-4 M) in 0.1 M MES buffer (pH
7.5). All compounds were excited using a UV light source at
302 nm except Eu-44 that was excited at 365 nm.
●

All compounds display red light characteristic of
Eu3+ complexes with varied intensities (Figure 5).

●

For lanthanide complexes to be useful in vivo, they
must demonstrate stability at physiological conditions
to ensure that free metals are not released in the body.
For a complex with poor kinetic stability, the metal ion
would easily dissociate from its ligand. This would
increase the distance between the metal and the
antenna and result in a reduction in emission intensity.
Although Eu-30, Eu-42, and Eu-44 exhibit adequate
luminescence intensities (Figures 3,4), they exhibit the
lowest kinetic stabilities (Figure 6).
Eu-43, Eu-46, and Eu-47 appear to be more stable
than the other complexes while also demonstrating
acceptable
luminescence
capabilities.
These
compounds appear to be more promising candidates
for future experimentation.

Evaluate the NMR and PARACEST MRI properties of
the library of complexes.
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